Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Recruiting now · Phase 1
Conditions studied: Acute Myeloid Leukemia, Myelodysplastic Syndrome
In brief
An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patient. A maximum of 27 r/r AML/MDS patients will be evaluated in this study in case of no dose limiting toxicity (DLT) and no replacement of patients.
Key facts
- Study ID
- NCT04167696
- Run by
- Celyad Oncology SA
- People needed
- 27
- Starts
- 2019-11-25
- Expected to finish
- 2035-02-01
- Last updated by the study team
- 2020-06-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Kansas Cancer Center — Fairway, Kansas, United States (enrolling)
- Uz Leuven — Leuven, Belgium (enrolling)
- Chu Liege — Liège, Belgium (enrolling)
- AZ DELTA — Roeselare, Belgium (enrolling)
- Mayo Clinic Cancer Center — Jacksonville, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.